Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson's Disease

Parkinson Disease Clinical Trial

— HALLUPARK  

Official title:

Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson's Disease

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03105401
• Other study ID #: 69HCL17_0137
• Status: Terminated
• Start date: May 15, 2017
• Est. completion date: April 25, 2018

Study information

• Verified date: January 2019
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to describe hallucinations prevalence in a sample of patients affected by Parkinson's disease and consulting in an outpatient facility.

An unique one hour interview will be offered to volunteers patients. Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.

The study hypothesis is that hallucinations prevalence in Parkinson's disease is underestimated and is higher than usually described in the scientific literature when all hallucinations modalities and minor hallucinatory phenomenons are searched for.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 32
• Est. completion date: April 25, 2018
• Est. primary completion date: April 25, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years-old

• Absence of opposition from the patient himself/herself or his/her legal representant for his/her participation to the study

• Patient without superior age limit with a diagnosis of Parkinson's disease made according to the UKPDSBB criteria (UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria)

• Outpatient consulting in neurology at the Charpennes'hospital

Exclusion Criteria:

• Opposition to the study

• Deafness or blindness which could compromise the interview

Related Conditions & MeSH terms

• Hallucinations
• Parkinson Disease

Intervention

Other:
• Assessment of hallucinations in Parkinson's disease
Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.

Locations

Country	Name	City	State
France	Hôpital des Charpennes. Centre de Recherche Clinique - vieillissement, cerveau, fragilité	Villeurbanne

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hallucinations Prevalence	Semi-structured questionnaire precisely describing hallucinations of all modalities and their characteristics, as well as minor hallucinations and delusions. Binary Yes/No possible answers.; Unique 1 hour interview to assess semi-structured questionnaire for primary outcome measurement, and psychometric scales.	1 hour